CDX Cardiex

China FDA Approval for Oscar 2 Blood Pressure Monitor with CardieX’s "SphygmoCor® Inside" Technology

China FDA Approval for Oscar 2 Blood Pressure Monitor with CardieX’s "SphygmoCor® Inside" Technology

SYDNEY, Australia, April 23, 2019 (GLOBE NEWSWIRE) -- CardieX Limited (Australian Stock Exchange listed: CDX) announces approval by the Chinese Food and Drug Administration (CFDA) of the Oscar 2 with “SphygmoCor® InsideAmbulatory Blood Pressure Monitor (ABPM), a product collaboration between CardieX wholly owned group company AtCor Medical (AtCor) and leading US blood pressure device manufacturer SunTech Medical Inc.

CFDA approval allows Oscar 2 ABPM with SphygmoCor® to be utilised by 20,000+ physicians, hospitals, clinics throughout China where ABPM is the most effective method of detection, diagnosis, monitoring and management of hypertension - a leading cause of more than 12% of annual adult deaths worldwide. Hypertension is a major and growing health disorder in China with over half the adult population currently affected. In China, a US$50M annual market opportunity.

Highlights

  • China FDA (CFDA) approval for Oscar 2 with “SphygmoCor® Inside” received; a market leading Ambulatory Blood Pressure Monitor (ABPM) for use in China for monitoring of central blood pressure.

     
  • Total addressable new CardieX revenue and market opportunity for sales of Oscar 2 with SphygmoCor® in China approximately $USD50 million annually - Potential for over 20,000 physicians, hospitals and clinics

     
  • Oscar 2 with SphygmoCor® is a successful existing collaboration between leading US based blood pressure monitor manufacturer and distribution company SunTech Medical, and CardieX wholly owned group company AtCor Medical.



  • CardieX’s SphymoCor® technology is the global gold standard in central blood pressure and arterial stiffness assessment, with over 1400 published studies and 4000+ global deployments.



  • Oscar 2 with SphygmoCor® will be the only available ABPM solution in China currently with “SphygmoCor inside” and provides a unique market differentiation for ABPM devices in this significant medical device segment.

     
  • CFDA approval in China expands existing collaboration between SunTech and CardieX for sales and distribution of Oscar 2 with SphygmoCor®. Device already FDA approved for sale in USA and is CE marked for sale in European Economic Area.

For more information please contact:

NWR Communication - Peter Taylor or Anne Leslie



EN
24/04/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cardiex

 PRESS RELEASE

CardieX and Mobvoi preparing for commercial launch of new smartwatch w...

CardieX and Mobvoi preparing for commercial launch of new smartwatch with advanced heart health features in US and Australia The two global companies announce imminent release of first-in-kind smartwatch NEWPORT BEACH, Calif. and SYDNEY, Australia, Oct. 19, 2021 (GLOBE NEWSWIRE) -- CardieX (CardieX, the Company) and Mobvoi are excited to announce significant progress towards commercialization and launch of a new smartwatch with first-in-class, advanced heart health features developed by ATCOR, a subsidiary of the Company. Pursuant to announcing their new commercial partnership in Septem...

 PRESS RELEASE

China FDA Approval for Oscar 2 Blood Pressure Monitor with CardieX’s...

China FDA Approval for Oscar 2 Blood Pressure Monitor with CardieX’s "SphygmoCor® Inside" Technology SYDNEY, Australia, April 23, 2019 (GLOBE NEWSWIRE) -- CardieX Limited (Australian Stock Exchange listed: CDX) announces approval by the Chinese Food and Drug Administration (CFDA) of the Oscar 2 with “SphygmoCor® Inside” Ambulatory Blood Pressure Monitor (ABPM), a product collaboration between CardieX wholly owned group company AtCor Medical (AtCor) and leading US blood pressure device manufacturer SunTech Medical Inc. CFDA approval allows Oscar 2 ABPM with SphygmoCor® to be utilised by 2...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch